Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Top Cited Papers
- 7 January 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 379 (9813), 315-321
- https://doi.org/10.1016/s0140-6736(11)61873-4
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2010
- Benefit of Adjuvant Chemotherapy for Resectable Gastric CancerJama-Journal Of The American Medical Association, 2010
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trialThe Lancet Oncology, 2010
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Nodal dissection for patients with gastric cancer: a randomised controlled trialThe Lancet Oncology, 2006
- Updates on esophageal and gastric cancersWorld Journal of Gastroenterology, 2006
- Gastric cancer—Patterns of relapse after surgical resectionSeminars in Radiation Oncology, 2002
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- Extended Lymph-Node Dissection for Gastric CancerNew England Journal of Medicine, 1999
- Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trialBritish Journal of Cancer, 1999